TB preventive therapy preferences among children and adolescents

Show simple item record

dc.contributor.author Strauss, M.
dc.contributor.author Wademan, D.T.
dc.contributor.author Mcinziba, A.
dc.contributor.author Hoddinott, G.
dc.contributor.author Rafique, M.
dc.contributor.author Jola, L.N.
dc.contributor.author Streicher, C.
dc.contributor.author Du Preez, K.
dc.contributor.author Osman, M.
dc.contributor.author Boffa, J.
dc.contributor.author Hausler, Harry
dc.contributor.author Hesseling, A.C.
dc.contributor.author Hirsch-Moverman, Y.
dc.date.accessioned 2024-08-06T12:44:07Z
dc.date.available 2024-08-06T12:44:07Z
dc.date.issued 2023-07
dc.description.abstract BACKGROUND : TB preventive therapy (TPT) is critical for ending TB, yet implementation remains poor. With new global guidelines expanding TPT eligibility and regimens, we aimed to understand TPT preferences among children, adolescents and caregivers. METHODS : We undertook a discrete choice experiment among 131 children, 170 adolescents and 173 caregivers, and conducted 17 in-depth interviews in 25 clinics in Cape Town, South Africa. The design included attributes for location, waiting time, treatment duration, dosing frequency, formulation/size, side effects, packaging and taste. Mixed-effects logistic regression models were used for analysis. RESULTS : Among children and caregivers, the number and size of pills, taste and side effects were important drivers of preferences. Among adolescents and caregivers, clinic waiting times and side effects were significant drivers of preferences. Adolescents expressed concerns about being stigmatised, and preferred services from local clinics to services delivered in the community. Dosing frequency and treatment duration were only significant drivers of choice among adolescents, and only if linked to fewer clinic visits. CONCLUSIONS : Introducing shorter TPT regimens in isolation without consideration of preferences and health services may not have the desired effect on uptake and completion. Developing TPT delivery models and formulations that align with preferences must be prioritised. en_US
dc.description.department Family Medicine en_US
dc.description.librarian am2024 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship The Bill & Melinda Gates Foundation (Seattle, WA, USA) through their support of the South African National TB Think Tank; the Fogarty International Center of the National Institutes of Health (Bethesda, MD, USA); and the European Union. en_US
dc.description.uri https://theunion.org/our-work/journals/ijtld en_US
dc.identifier.citation Strauss, M. Wademan, D.T., Mcinziba, A. et al. 2023, 'TB preventive therapy preferences among children and adolescents', International Journal of Tuberculosis and Lung Disease, vol. 27, no. 7, pp. 520-529. http://dx.DOI.org/10.5588/ijtld.22.0645. en_US
dc.identifier.issn 1027-3719 (print)
dc.identifier.issn 1815-7920 (online)
dc.identifier.other 10.5588/ijtld.22.0645
dc.identifier.uri http://hdl.handle.net/2263/97460
dc.language.iso en en_US
dc.publisher International Union Against Tuberculosis and Lung Disease en_US
dc.rights © 2023 The Union. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. en_US
dc.subject Discrete choice experiment en_US
dc.subject Patient-centred care en_US
dc.subject Children en_US
dc.subject Preferences en_US
dc.subject Tuberculosis preventive therapy (TPT) en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title TB preventive therapy preferences among children and adolescents en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record